The data showed that ZFX expression was significantly higher in CML CD34+ cells than in NBM CD34+ cells, and ZFX expression was significantly higher in blast crisis patients than in chronic phase patients (Fig. 1A). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.